Showing 1-8 of 8 results for "I9010"
Jane A Potter et al.
Journal of virology, 86(23), 12923-12932 (2012-09-21)
The E2 envelope glycoprotein of hepatitis C virus (HCV) binds to the host entry factor CD81 and is the principal target for neutralizing antibodies (NAbs). Most NAbs recognize hypervariable region 1 on E2, which undergoes frequent mutation, thereby allowing the...
S Küpcü et al.
Journal of immunological methods, 196(1), 73-84 (1996-09-13)
In the present study, cup-shaped 1-3 microns large cell wall fragments from Thermoanaerobacter thermohydrosulfuricus L111-69 covered with a hexagonal S-layer lattice composed of glycoprotein subunits were shown to act as a matrix for the immobilization of human IgG. After cross-linking...
null
Wei Wang et al.
Journal of pharmaceutical sciences, 96(1), 1-26 (2006-09-26)
The number of therapeutic monoclonal antibody in development has increased tremendously over the last several years and this trend continues. At present there are more than 23 approved antibodies on the US market and an estimated 200 or more are...
Molecular Genetics of Immunoglobulin (1987)
Label-free biodetection using capacitive micromachined ultrasonic transducers (CMUTs) and its application for cardiovascular disease diagnostics
Eaimkhong S, et al.
Journal of nanomedicine & nanotechnology, 3(144), 2-2 (2012)
The Immunoglobulins: Structure and Function (1998)
Hannes Orelma et al.
Biomacromolecules, 13(9), 2802-2810 (2012-07-27)
We investigated the adsorption and chemical conjugation of avidin and its deglycosylated form, neutravidin, on films of regenerated and nanofibrillar cellulose. The dynamics and extent of biomolecular attachment were monitored in situ by quartz crystal microbalance microgravimetry and ex situ...

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.